Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta2-agonists for asthma: the pediatric perspective.

Padmaja Subbarao1, Felix Ratjen

  • 1Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. padmaja.subbarao@sickkids.ca

Clinical Reviews in Allergy & Immunology
|November 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Post-infectious bronchiolitis obliterans in children: pathogenesis, treatment strategies, and future directions.

Current opinion in pediatrics·2026
Same author

Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.

Respiratory medicine·2026
Same author

The Impact of Nutritional Status on Lung Function Trajectories in Pediatric Patients With Primary Ciliary Dyskinesia.

Pediatric pulmonology·2026
Same author

Treatment with elexacaftor/tezacaftor/ivacaftor does not alter SpiroNose-derived electronic breath profiles in children with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026

Inhaled beta-agonists are common for infant wheezing, but may harm lung health. This review examines their development, use, and potential negative effects in children.

Area of Science:

  • Pediatric Pulmonology
  • Pharmacology

Background:

  • Inhaled beta-agonists are widely used for pediatric wheezing disorders.
  • Concerns exist regarding their potential adverse effects on lung health and symptoms.

Purpose of the Study:

  • To review beta-agonist receptor and smooth muscle development in children.
  • To evaluate the clinical utility of beta-agonists in pediatric wheezing and asthma.
  • To discuss the potential detrimental effects of beta-agonists in this population.

Main Methods:

  • Literature review of developmental biology.
  • Synthesis of evidence on clinical efficacy.
  • Discussion of safety data for beta-agonist medications.

Main Results:

Related Experiment Videos

  • Beta-agonist receptors and smooth muscle mature throughout fetal and childhood development.
  • Evidence for clinical utility in wheezing infants and asthmatic children is reviewed.
  • Potential detrimental effects of both short- and long-acting beta-agonists are considered.

    • Conclusions:

    • The use of inhaled beta-agonists in children requires careful consideration of developmental factors.
    • Further research is needed to fully understand the long-term safety and efficacy profiles.
    • Balancing benefits and risks is crucial for optimal management of pediatric respiratory conditions.